Tag - Immusoft

Immusoft Receives $4M in Funding from the California Institute for Regenerative Medicine (CIRM)

Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP-002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options. MPS II is a rare genetic disease in children, which […]

Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers

Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and lymphoma. Current treatments can be effective, but in those patients that do not respond, there are few treatment options. Today, the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing $4.1 million in a therapy aimed at helping patients who have failed standard therapy. The CIRM Board also approved investing $44,101,935 in 11 projects as part […]

Takeda bets up to $900M on Immusoft’s cell therapies for neurometabolic disorders

 
 
 
 
 
 
 
Immusoft has inked its first Big Pharma collaboration in a deal with biotech’s best friend Takeda worth up to $900 million that sees the pair work on cell therapies in rare inherited disorders. The pact will focus on neurometabolic disorders, Immusoft said Wednesday. The deal comes as the Seattle-based biotech nears the clinic for the first time in its decadelong journey working on sustained protein delivery for rare diseases. Read more >>

Immusoft Announces Formation of Scientific Advisory Board

Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs. The SAB will work closely with the Immusoft leadership team to advance and expand its leadership position in B cells as biofactories for therapeutic protein delivery, a novel approach that Immusoft has pioneered. Read more […]

Seattle gene therapy biotech startup Immusoft raises $4.5M

Seattle-based biotech startup Immusoft raised another $4.5 million and landed a $467,000 NIH grant to help further development of its drugs that treat genetic diseases. Founded in 2009, Immusoft develops immune cell technology that uses blood cells from a patient to create therapeutic proteins targeted to treat diseases. Its lead candidate, ISP-001, treats Mucopolysaccharidosis type I, or MPS I, and has both orphan drug and rare pediatric disease designations from the FDA. Read more >>